![]() |
|
|
My Amedeo
FAQ
Privacy
About
|
|
|||||||||
Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK. |
| Liver Diseases |
|
Free Subscription
2 Am J Gastroenterol |
Retrieve available abstracts of this week’s articles:
HTML format |
| Single Articles |
AMEDEO Liver Diseases is free of charge.
Practical Applications of Artificial Intelligence to Improve Efficiency and
Reduce Burnout in Gastroenterology and Hepatology Practices.
Am J Gastroenterol. 2025 Dec 16. doi: 10.14309/ajg.0000000000003887.
PubMed
Association of SGLT2 Inhibitors with Reduced Hepatocellular Carcinoma Risk in
Patients with Type 2 Diabetes.
Am J Gastroenterol. 2025 Dec 16. doi: 10.14309/ajg.0000000000003889.
PubMed
Abstract available
Betaine supplementation prevents ethanol-induced disruption of intestinal tight
junction integrity and liver inflammation in rats.
Biochem Biophys Res Commun. 2026;794:152997.
PubMed
Abstract available
TARDBP upregulates GJB2 to promote tumor progression in hepatocellular carcinoma.
Biochem Biophys Res Commun. 2025;796:153123.
PubMed
Abstract available
Splicing factor SF3B4 promotes mitochondrial glutamine metabolism in
hepatocellular carcinoma by regulating GLS1 isoform switching.
Biochem Biophys Res Commun. 2025;796:153134.
PubMed
Abstract available
Association of the YTHDF2 rs3738067 A>G variant with hepatoblastoma risk: a
multicenter case-control study in Chinese children.
BMC Cancer. 2025 Dec 17. doi: 10.1186/s12885-025-15478.
PubMed
Impact of metabolic and bariatric surgery on MASLD: histological resolution and
metabolic outcomes in a retrospective cohort.
BMC Gastroenterol. 2025;25:864.
PubMed
Abstract available
Aspirin reduces short-term mortality risk in critically ill patients with liver
cirrhosis: a propensity-score matched retrospective analysis using the MIMIC-IV
database.
BMC Gastroenterol. 2025 Dec 18. doi: 10.1186/s12876-025-04499.
PubMed
"Noninvasive predictive marker for esophageal variceal bleeding".
BMC Gastroenterol. 2025 Dec 18. doi: 10.1186/s12876-025-04567.
PubMed
Clinicopathological features of steroid-refractory immune-mediated hepatotoxicity
induced by immune checkpoint inhibitors.
BMC Gastroenterol. 2025 Dec 17. doi: 10.1186/s12876-025-04561.
PubMed
Abstract available
Exploring the biliary microbiome in hepatopancreatobiliary disorders: a
comprehensive systematic review of microbial signatures and diagnostic potential.
BMC Gastroenterol. 2025 Dec 17. doi: 10.1186/s12876-025-04551.
PubMed
Abstract available
Development of a nomogram for predicting the long-term risk of hepatocellular
carcinoma after antiviral treatment for hepatitis C.
BMC Gastroenterol. 2025;25:860.
PubMed
Abstract available
Branched-Chain Amino Acid Supplementation in Patients with Cirrhosis: Boon, Bust,
or Bull?
Dig Dis Sci. 2025 Dec 16. doi: 10.1007/s10620-025-09614.
PubMed
A case of cirrhosis with gastric varices and hypersplenism treated by endoscopic
ultrasound-guided devascularization and partial splenic embolization (with
video).
Endoscopy. 2025;57.
PubMed
Endoscopic recanalization of a complete choledochojejunal anastomotic stricture
using the "piercing technique" via an endoscopic ultrasound-guided
hepaticogastrostomy approach.
Endoscopy. 2025;57.
PubMed
Analysis of tissue copper levels as a reliable diagnostic tool in paediatric
liver disease.
Eur J Pediatr. 2025;185:23.
PubMed
Abstract available
Performance of simulated abbreviated liver MRI combined with CT for liver
metastasis screening in rectal cancer staging.
Eur Radiol. 2026;36:666-675.
PubMed
Abstract available
Toward perioperative, numerically assisted irreversible electroporation for
hepatocellular carcinoma: clinical outcomes informed by numerical simulations.
Eur Radiol. 2025 Dec 19. doi: 10.1007/s00330-025-12223.
PubMed
Abstract available
Outcomes of Endoscopic ultrasound-guided liver biopsy using 22-gauge versus
19-gauge needles with a novel hydrostatic sampling technique.
Gastrointest Endosc. 2026;103:98-108.
PubMed
Abstract available
An alpha-specific PI3K inhibitor improves chemotherapy efficacy by inhibiting hepatic
stellate cell activation in liver cancer.
Hepatology. 2025 Dec 8. doi: 10.1097/HEP.0000000000001639.
PubMed
Abstract available
Hepatocellular carcinoma with macrovascular invasion: Review and survival
meta-analysis of initial local therapy using minimal prognostic criteria.
Hepatology. 2025 Dec 15. doi: 10.1097/HEP.0000000000001630.
PubMed
Abstract available
Myeloid CD36 deficiency alleviates hepatic fibrosis by promoting adaptive
immunity of macrophage.
Hepatology. 2025 Dec 16. doi: 10.1097/HEP.0000000000001646.
PubMed
Abstract available
PSC and HCC: Age and cirrhosis draw the line on risk.
Hepatology. 2026;83:1.
PubMed
Breaching the blood-brain barrier: Functional MRI changes in covert hepatic
encephalopathy.
Hepatology. 2026;83:4-5.
PubMed
Reply to 'Nuances in POCUS-guided hemodynamic assessment in cirrhosis'.
Hepatology. 2025 Dec 17. doi: 10.1097/HEP.0000000000001653.
PubMed
Nuances in POCUS-guided hemodynamic assessment in cirrhosis.
Hepatology. 2025 Dec 17. doi: 10.1097/HEP.0000000000001648.
PubMed
Hyperinsulinemia, an overlooked clue and potential way forward in metabolic
dysfunction-associated steatotic liver disease.
Hepatology. 2026;83:169-177.
PubMed
Abstract available
Sex and gender in alcohol use disorder and alcohol-associated liver disease in
the United States: A narrative review.
Hepatology. 2026;83:178-194.
PubMed
Abstract available
Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat
content: Systematic review and network meta-analysis.
Hepatology. 2026;83:117-126.
PubMed
Abstract available
Proton density fat fraction for diagnosis of metabolic dysfunction-associated
steatotic liver disease.
Hepatology. 2026;83:127-141.
PubMed
Abstract available
Targeting the ER stress sensor IRE1 protects the liver from fibrosis through the
downregulation of the proteostasis factor P4HB/PDIA1.
Hepatology. 2026;83:75-93.
PubMed
Abstract available
Reply to: "Revisiting Methodologic Paradigms in Local Therapies for
Hepatocellular Carcinoma: Insights From the SURF Study" and "Methodologic and
Reporting Gaps in the SURF Trial".
J Clin Oncol. 2025 Dec 19:JCO2502390. doi: 10.1200/JCO-25-02390.
PubMed
Revisiting Methodologic Paradigms in Local Therapies for Hepatocellular
Carcinoma: Insights From the SURF Study.
J Clin Oncol. 2025 Dec 19:JCO2501536. doi: 10.1200/JCO-25-01536.
PubMed
Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD
phase II randomized-controlled trial.
J Hepatol. 2025 May 8:S0168-8278(25)00252-1. doi: 10.1016/j.jhep.2025.
PubMed
Abstract available
Patient-derived liver organoids recapitulate liver epithelial heterogeneity and
enable precision modeling of alcohol-related liver disease.
J Hepatol. 2026;84:135-149.
PubMed
Abstract available
Decreased LONP1 expression exacerbates MASH-induced liver fibrosis via elevated
orotic acid levels.
J Hepatol. 2026;84:165-180.
PubMed
Abstract available
Sex-related variations in liver homeostasis and disease: From zonation dynamics
to clinical implications.
J Hepatol. 2026;84:181-193.
PubMed
Abstract available
Healthy eating and physical activity significantly lower sex-specific
alcohol-attributable liver mortality in the United States.
J Hepatol. 2026;84:18-34.
PubMed
Abstract available
Cellular senescence in liver diseases: From molecular drivers to therapeutic
targeting.
J Hepatol. 2026;84:194-212.
PubMed
Abstract available
Phase II INTEGRIS-PSC trial of bexotegrast, an alphavbeta6/alphavbeta1 integrin inhibitor, in
primary sclerosing cholangitis.
J Hepatol. 2025 Sep 26:S0168-8278(25)02498-5. doi: 10.1016/j.jhep.2025.
PubMed
Abstract available
Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis.
N Engl J Med. 2025;393:2434-2446.
PubMed
Abstract available
The reciprocal relationship between non-alcoholic fatty liver disease and
hypothyroidism: A systematic review and meta-analysis of about 39 million
individuals.
PLoS One. 2025;20:e0338413.
PubMed
Abstract available
Efficacy and safety of Atezolizumab plus Bevacizumab and Lenvatinib as first-line
systemic therapies for hepatocellular carcinoma: A real-world study.
PLoS One. 2025;20:e0337351.
PubMed
Abstract available
Contrast-enhanced US Evaluation of Residual Hepatocellular Carcinoma Following
Lenvatinib Combined with Anti-PD-1 Antibody Downstaging Therapy.
Radiology. 2025;317:e251698.
PubMed
Abstract available
Hepatocellular Carcinoma Presenting as Bile Duct Tumor Thrombus without Obvious
Intrahepatic Mass.
Radiology. 2025;317:e251418.
PubMed
Thank you for your interest in scientific medicine.